H.R. 679 was introduced on January 23, 2025 by Rep. Diana Harshbarger and colleagues.
The bill would nullify the modifications the Food and Drug Administration made in January 2023 to the risk evaluation and mitigation strategy (REMS) for the abortion pill mifepristone. It would also prohibit the Secretary of Health and Human Services or any agency from establishing, implementing, or enforcing any REMS for mifepristone that is substantially similar to those nullified modifications.
The measure does not, in the text provided, propose a replacement REMS framework or other safety mechanism beyond undoing the 2023 changes.
At a Glance
What It Does
The bill nullifies the January 2023 FDA modifications to the REMS for mifepristone under 21 U.S.C. 355–1 and bars substantially similar REMS provisions in the future.
Who It Affects
Directly impacts FDA and HHS, manufacturers and distributors of mifepristone, and healthcare providers who prescribe or dispense it, as well as patients seeking abortion using mifepristone.
Why It Matters
It would revert federal oversight to a pre-2023 posture, creating nationwide uniformity in REMS policy while potentially changing access dynamics and safety oversight for mifepristone.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill centers on the REMS for mifepristone, a federal safety framework designed to manage the drug’s risks. Section 1(a) nullifies the January 2023 modifications the FDA made to that REMS under the Federal Food, Drug, and Cosmetic Act, effectively wiping those changes from the record.
Section 1(b) goes further by prohibiting the Secretary of Health and Human Services or any federal office from establishing, implementing, or enforcing any REMS for mifepristone that is substantially similar to the modifications that were nullified. In short, the bill seeks to restore the regulatory regime that existed prior to the January 2023 changes and blocks similar alterations in the future.
The bill, as introduced, does not specify an alternative REMS framework or safety mechanism to replace the 2023 modifications. It focuses on undoing existing changes rather than delineating a new regulatory approach.
The lack of a proposed replacement implies a return to the status quo ante, with the potential for interstate regulatory variation to re-emerge if states interpret or implement policies differently in the absence of a federal modernization effort.From a compliance perspective, the measure would require federal agencies to cease pursuing or enforcing modifications to REMS for mifepristone that mirror the 2023 changes and would anchor any future decisions in a framework prior to those changes. Stakeholders should monitor any amendments that could accompany the bill in committee or during floor action, as those could alter safety oversight or access considerations for patients and providers.
The Five Things You Need to Know
The bill nullifies the January 2023 REMS modifications for mifepristone under 21 U.S.C. 355-1.
It prohibits any future REMS provisions for mifepristone that are substantially similar to the nullified changes.
The measure targets federal REMS authority and does not specify an alternative safety framework.
Introduced in the 119th Congress by Rep. Diana Harshbarger and colleagues, referred to the Committee on Energy and Commerce.
There is no replacement framework or new safety mechanism proposed in the text provided.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Nullification of FDA REMS modifications for mifepristone
Section 1(a) states that the modifications made by the FDA in January 2023 to the REMS for mifepristone under 21 U.S.C. 355-1 are hereby nullified. In plain terms, the bill seeks to erase those changes from the regulatory record and restore the prior REMS framework that existed before January 2023.
Section 1(b) adds a prohibition: the Secretary of Health and Human Services (or any head of any office, department, or agency within HHS) shall not establish, implement, or enforce any REMS for mifepristone that is substantially similar to any of the modifications that were nullified by subsection (a). This creates a nationwide bar on recreating the specific regulatory approach that existed post-2023 changes, effectively freezing the REMS policy for mifepristone in a pre-modification state.
No substantially similar REMS provisions
Although the bill’s text provided stops after Section 1, the explicit prohibition in Section 1(b) covers future REMS actions by federal agencies. The practical effect is a directive to maintain the status quo ante and to avoid crafting REMS provisions for mifepristone that replicate the 2023 changes, thereby limiting adaptive regulatory responses from federal agencies going forward.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Federal and state health agencies seeking uniform nationwide standards for REMS oversight could benefit from predictable federal policy.
- Hospitals, clinics, and health systems that want a clear, consistent federal framework for prescribing and dispensing mifepristone may prefer a single, pre-2023 standard.
- Pharmacy chains and distributors with established REMS compliance processes aligned to the pre-2023 regime may face a more stable operating environment under a consistent, older framework.
- Professional medical associations advocating for clear, stable regulatory oversight of abortion medications may view the rollback as reducing regulatory complexity and litigation risk.
Who Bears the Cost
- Patients may face increased access barriers if the prior REMS was more restrictive and the rollback preserves or reintroduces those restrictions.
- Small clinics and independent prescribers that must navigate REMS obligations could experience increased administrative burden if the status quo ante is complex or if compliance varies by state.
- Pharmacies and wholesalers that had adapted to the 2023 changes may incur costs to re-align their REMS processes with the pre-2023 regime.
- Health systems with extensive REMS-related workflows could incur transition costs and potential service disruption during any period of regulatory readjustment.
- State and local regulators might encounter new enforcement or coordination challenges when federal REMS policy freezes into a pre-2023 regime.
Key Issues
The Core Tension
The central dilemma is safety versus access: restoring a pre-2023 REMS posture may simplify compliance for some stakeholders but could reduce the scope for targeted safety improvements that the 2023 changes sought to implement.
The bill’s approach creates a clear policy choice: restore the prior REMS framework for mifepristone and block future, similar changes. This raises tensions between safety oversight and access to medication abortion.
A key concern is whether rolling back the 2023 modifications weakens or strengthens patient safety data collection, provider oversight, and consistent nationwide practices. The absence of an alternative safety mechanism means that any improvements or refinements in REMS policy would have to wait for future legislative action, potentially prolonging regulatory uncertainty.
Another tension lies in federal-state dynamics. A pre-2023 REMS framework may interact differently with state laws and policies on abortion, possibly increasing interstate variance in how mifepristone is dispensed and monitored.
Enforcement challenges could emerge if federal standards are perceived as inconsistent with state regulatory environments or with clinical practices across jurisdictions.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.